AI assistant
CalciMedica, Inc. — Director's Dealing 2024
Feb 6, 2024
34649_dirs_2024-02-06_5e116210-8a33-458f-8c3a-115bdac21b58.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CalciMedica, Inc. (CALC)
CIK: 0001534133
Period of Report: 2024-02-05
Reporting Person: Roberts Eric W (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-05 | Common Stock | A | 91086 | $4.2665 | Acquired | 111373 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-05 | Warrant | $5.36 | A | 45543 | Acquired | 2024-12-31 | Common Stock (45543) | Direct |
| 2024-02-05 | Warrant | $7.15 | A | 45543 | Acquired | 2026-12-31 | Common Stock (45543) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 35894 | Indirect |
| Common Stock | 5223 | Indirect |
| Common Stock | 10661 | Indirect |
| Common Stock | 356989 | Indirect |
| Common Stock | 66228 | Indirect |
| Common Stock | 316109 | Indirect |
Footnotes
F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.
F3: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F4: The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.